Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 836 Views
-
Last post by NHE
-
- 0 Replies
- 2465 Views
-
Last post by frodo
-
- 0 Replies
- 1123 Views
-
Last post by NHE
-
- 1 Replies
- 1118 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1409 Views
-
Last post by frodo
-
- 0 Replies
- 1666 Views
-
Last post by NHE
-
- 0 Replies
- 2199 Views
-
Last post by vesta
-
- 0 Replies
- 1654 Views
-
Last post by frodo
-
- 0 Replies
- 2288 Views
-
Last post by DIM